Clinical trial results expected in the weeks ahead could push shares of these small-cap drugmakers through the roof.

Tyr Pharma's Phase 2 data for efzo in pulmonary sarcoidosis is difficult to interpret and not predictive for Phase 3. Read ...

Scientists discovered chemical reactions that place amino acids on tRNAs and extend peptide chains without enzymes, a key ...

A promising new study has identified a highly accurate, non-invasive method to diagnose non-small cell lung cancer (NSCLC) ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access . * An analyst from ...

Alltrna, the preclinical Flagship Pioneering-backed biotech trying to turn transfer RNA (tRNA) into drugs, is slimming down as it works toward the clinic. | Alltrna, the preclinical Flagship ...

As the Dow Jones Industrial Average touches an all-time high and the tech-heavy Nasdaq Composite experiences a slump, investors are closely monitoring Federal Reserve signals amid a busy earnings ...

Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in ...

The amino acid binding domains of the tryptophanyl (TrpRS)- and tyrosyl-tRNA synthetases (TyrRS) of Bacillus stearothermophilus are highly homologous. These similarities suggest that conserved ...

Aminoacyl-tRNA synthetases (aaRSs) catalyze aminoacylation of tRNAs in the first step of protein synthesis in the cytoplasm. However, in higher eukaryotes, they acquired additional functions beyond ...